Evidence map›Paper›PMID 33312078›Full record

ArticleJournal of interventional cardiology2020

Major Bleeding Events Are Stronger Predictors of Long-Term Mortality Than Coronary Events in Secondary Prevention Therapy for Ischaemic Heart Disease.

Shigetaka Kageyama, Koichiro Murata, Ryuzo Nawada, Tomoya Onodera, Yuichiro Maekawa

Open access · goldAbstract read
In one paragraph

Article in Journal of interventional cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 73% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Shigetaka KageyamaDepartment of Cardiology, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.ORCID https://orcid.org/0000-0003-4982-3203
Koichiro MurataDepartment of Cardiology, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.
Ryuzo NawadaDepartment of Cardiology, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.
Tomoya OnoderaDepartment of Cardiology, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.
Yuichiro MaekawaInternal Medicine III, Hamamatsu University School of Medicine, Shizuoka, Japan.
Shizuoka City Hospital · JPHamamatsu University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSecondary prevention of ischaemic heart disease (IHD) is an important aspect of healthcare. To improve the prognosis of and control risk factors for IHD patients, we created a unique referral system called the Shizuoka IHD patient registry.

methodsFrom 2009 to 2013, we enrolled 1240 patients; they participated in follow-up until 2018. The risk factor target values were as follows: low-density-lipoprotein cholesterol, <100 mg/dl; glycated haemoglobin of diabetes patients, <7%; systolic blood pressure, <130 mmHg; and diastolic blood pressure, <80 mmHg (mean follow-up interval, 2001 ± 794 days). The cumulative incidence rates were 10.8% for all-cause death (cardiac death, 1.5%), 15.7% for coronary events, and 2.6% for major bleeding. Patients were separated into the major bleeding group (

resultsWe observed significant differences in age, rate antithrombotic drug use, and mortality. A Kaplan-Meier analysis of all-cause death showed significant differences between the event-free and major bleeding groups (

conclusionMajor bleeding events were stronger predictors of long-term mortality than coronary events during the long-term follow-up of stable IHD.

Indexed as

Acute Coronary SyndromeHemorrhageMyocardial IschemiaAgedFemaleFibrinolytic AgentsHeart Disease Risk FactorsHumansIncidenceJapanKaplan-Meier EstimateMalePrognosisProportional Hazards ModelsReferral and ConsultationSecondary PreventionFibrinolytic Agents

Identifiers

PMID33312078
PMCPMC7721507
OpenAlexW3109208481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.